This will be needed within the next 18 hours, the paper will…

This will be needed within the next 18 hours, the paper will be 8 page and it’s a summary with corrections of the paper attached. Also need new articles that include the research done for this topic. I need this ASAP. Articles below. Please also include the articles in the attachment, no need to research new articles, you can get all the information from the attached. Topic: How MDMA can help treat PTSD

Title: MDMA-Assisted Psychotherapy for PTSD: A New Perspective


Post-traumatic stress disorder (PTSD) is a debilitating psychiatric condition that affects millions of individuals worldwide. Traditional treatment modalities, such as cognitive-behavioral therapy and pharmacotherapy, have shown limited success in providing long-term relief for PTSD symptoms. However, recent research has shown promising results using MDMA (3,4-methylenedioxy-methamphetamine)-assisted psychotherapy as a potential tool to mitigate the impact of PTSD. This paper aims to summarize and critique two seminal articles on the topic, examine the potential mechanisms of action of MDMA, and discuss implications for future research.

Summary and Critique of Selected Articles:

The first article, authored by Mithoefer et al. (2010), titled “The Safety and Efficacy of MDMA-Assisted Psychotherapy for Chronic, Treatment-Resistant PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Pilot Study,” explores the use of MDMA-assisted psychotherapy in twelve subjects with chronic treatment-resistant PTSD. The study employed a randomized, double-blind, placebo-controlled design and demonstrated a significant reduction in PTSD symptoms after three MDMA-assisted psychotherapy sessions compared to the placebo group. The authors concluded that MDMA may enhance the therapeutic process by reducing fear and defensiveness and promoting emotional insight.

While the study by Mithoefer et al. (2010) provides preliminary evidence for the efficacy of MDMA-assisted psychotherapy in PTSD, it has several limitations. The small sample size and lack of long-term follow-up limit the generalizability and durability of the reported improvements. A larger-scale study with a longer-term evaluation would be beneficial to establish the long-term safety and efficacy of MDMA-assisted psychotherapy for PTSD.

The second article, authored by Ot’alora et al. (2018), titled “3,4-Methylenedioxymethamphetamine-assisted Psychotherapy for Treatment of Chronic Posttraumatic Stress Disorder: A Randomized Phase 2 Controlled Trial,” investigates the effects of MDMA-assisted psychotherapy in twenty-eight individuals with chronic PTSD. The study employed a randomized, active-placebo-controlled design and revealed a significant reduction in PTSD symptoms in the MDMA group compared to the active placebo group. The authors suggest that the therapeutic benefits of MDMA may be attributed to increased emotional introspection, trust, and empathy.

Despite the strengths of Ot’alora et al.’s (2018) study, such as the larger sample size and an adequate control group, several limitations should be acknowledged. The lack of long-term follow-up and the potential for placebo effects warrant further investigation. Additionally, future research should address potential confounding factors, such as co-existing psychiatric conditions and prior treatment history.

Potential Mechanisms of Action:

The mechanisms through which MDMA-assisted psychotherapy may exert its therapeutic effects in PTSD are still not fully understood. However, researchers have proposed several potential mechanisms based on available evidence. MDMA’s pharmacological properties, including its ability to enhance empathy, promote emotional release, and reduce fear and defensiveness, have been linked to its therapeutic benefits in the treatment of PTSD. MDMA’s effects on neurotransmitter systems, particularly serotonin, as well as its impact on neural circuits involved in fear processing and emotional regulation, are also under investigation.

Furthermore, the therapeutic process facilitated by MDMA-assisted psychotherapy, where a trained therapist provides a supportive and non-judgmental environment, aids in processing traumatic experiences. The empathogenic properties of MDMA may enhance the therapeutic alliance, leading to increased trust and openness, which are crucial factors in successful psychotherapy outcomes. Additionally, the peak effects of MDMA coincide with the start of the psychotherapy session, which may provide an optimal window for targeted intervention and emotional processing.

Implications for Future Research:

The emerging evidence supporting the potential therapeutic benefits of MDMA-assisted psychotherapy in PTSD necessitates further investigation. Future research should focus on conducting larger-scale, adequately powered randomized controlled trials with long-term follow-up to establish the generalizability, long-term safety, and sustained efficacy of this treatment approach. Additionally, studies should explore subgroups of PTSD patients who may benefit the most from MDMA-assisted psychotherapy, such as individuals with treatment-resistant symptoms or those with extensive trauma histories.


In conclusion, MDMA-assisted psychotherapy shows promise as a novel and potentially transformative approach for the treatment of PTSD. The summarized articles provide preliminary evidence supporting the efficacy of this treatment modality. However, further research is warranted to address the limitations and gaps in knowledge surrounding MDMA-assisted psychotherapy in order to establish it as an evidence-based treatment option for individuals suffering from PTSD.